



Forced Vital Capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis

Mariann I. Lassenius, Iiro Toppila, Nora Pöntynen, Laura Kasslin, Jaana Kaunisto, Maritta Kilpeläinen & Tarja Laitinen

To cite this article: Mariann I. Lassenius, Iiro Toppila, Nora Pöntynen, Laura Kasslin, Jaana Kaunisto, Maritta Kilpeläinen & Tarja Laitinen (2020) Forced Vital Capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis, European Clinical Respiratory Journal, 7:1, 1702618, DOI: [10.1080/20018525.2019.1702618](https://doi.org/10.1080/20018525.2019.1702618)

To link to this article: <https://doi.org/10.1080/20018525.2019.1702618>



© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



Published online: 17 Dec 2019.



Submit your article to this journal [↗](#)



Article views: 216



View related articles [↗](#)



View Crossmark data [↗](#)

Forced Vital Capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis

Mariann I. Lassenius^a, Iiro Toppila^a, Nora Pöntynen^b, Laura Kasslin^b, Jaana Kaunisto^c, Maritta Kilpeläinen^c and Tarja Laitinen^d

^aMedaffcon Oy, Espoo, Finland; ^bBoehringer Ingelheim KY, Helsinki, Finland; ^cDepartment of Pulmonary Diseases, Turku University Hospital and University of Turku, Turku, Finland; ^dHospital administration, Tampere University Hospital, Tampere, Finland

ABSTRACT

Aim of the study: Potential care implications of antifibrotic reimbursement restrictions were studied by forced vital capacity (FVC) decline, mortality and specialty care related healthcare resource utilization in patients with idiopathic pulmonary fibrosis (IPF).

Material and methods: IPF patients were identified from the electronic medical records of the Hospital District of Southwest Finland between 2005 and 2017. Text-mining was used for patient identification to exclude other interstitial lung diseases (ILD) from the cohort. FVC reimbursement restriction (FVC 50-90%) was used for stratification.

Results: Out of all patients with ILD, 27% (N = 266) were identified to have IPF. At baseline, 24% presented with FVC >90% and 63% with FVC 50-90% predicted. FVC at diagnosis did not improve during the study period. Median survival decreased by severity from 6.7 years in FVC >90% at baseline to 0.7 years in patient with FVC <50% predicted. In the FVC >90% group, 14% died before a change in FVC category could be noted. Overall, 4.7 million euro worth of specialty care resources were spent on IPF patients. The highest cost driver was inpatient days.

Conclusions: IPF is associated with a high burden of disease, and reimbursement restrictions are in conflict with early care. As there are antifibrotic treatment options for IPF patients, early diagnosis is important.

ARTICLE HISTORY

Received 3 June 2019
Accepted 28 November 2019

KEYWORDS

IPF; FVC decline; mortality; healthcare resource utilization

Introduction

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrotic lung disease causing disrupted gas exchange, respiratory failure and death [1,2]. Disease mechanisms include genetic and environmental factors but are poorly understood [1,2]. Substantial international efforts have unified and improved IPF diagnostics and treatment recommendations [1,3–7]. The diagnosis is based on the histological and/or radiological appearance of a usual interstitial pneumonia (UIP) pattern, while excluding other interstitial lung diseases (ILD) [1,5].

IPF prevalence estimates vary from 2–29 cases/100 000 persons, with 8.6–19 cases/100 000 persons in Finland [1,8,9]. Differing study designs and historically ununiform definitions likely explain the variability in prevalence. In Finland, IPF and other ILD are diagnosed under ICD-10 code J84.1, leading to challenges in distinguishing between the diseases in retrospective studies, however, estimates are that 20–30% of these patients have IPF [9,10].

Due to strict inclusion and exclusion criteria, generalizing randomized clinical trial (RCT) data to real

life remains challenging [11]. RCTs mainly investigated IPF patients with moderate physiological impairment, or even excluded those with forced vital capacity (FVC) >90% predicted [12–15]. Although post-hoc analyses show similar antifibrotic therapy responses between patients with preserved and significantly impaired lung function, the limited nature of the data has restricted reimbursement in many countries [16,17]. In Finland, the antifibrotic treatment reimbursement threshold is FVC 50-90% predicted [18].

IPF associates with a substantial humanistic and healthcare burden. Yet, information on disease burden and mortality by baseline FVC category is largely lacking [19–24]. Further, many studies assessing healthcare resource utilization (HCRU) have been claims based, leading to potential selection bias and unavailability of clinical data [19,23,24]. Because of reimbursement restrictions, FVC decline, mortality and HCRU are of high interest. Therefore, the aims of this study were to assess IPF progression measured by FVC decline, mortality, and healthcare resource utilization by disease

severity in data reflecting real clinical practice and reimbursement restrictive categories.

Material and methods

Adult patients with ICD-10 codes for other interstitial pulmonary diseases with fibrosis or unspecified interstitial pulmonary disease (J84.1 or J84.9), at the Hospital District of Southwest Finland (HDSWF) during the years 2005–2017 were included in this retrospective registry based study (N = 993), and electronic medical records (EMR) were analysed. From the initial cohort, 266 IPF patients were identified based on high-resolution computed tomography (HRCT) and/or lung biopsy statements and clinical diagnosis. IPF patients were followed from the first J84.1 or J84.9 diagnosis (= index) until the end of 2017, the initiation of antifibrotic treatment (pirfenidone or nintedanib), death, or until lost to follow-up, defined as no specialty care contact in 18 months.

IPF cohort selection

For inclusion, fibrotic changes corresponding to IPF in HRCT or lung biopsy statements in addition to diagnosis of IPF symptoms in EMR were required. A clinical expert defined text patterns of affirmative and negative phrases for text-mining from the five most recent entries in the EMR (Table A1). Affirmative phrases yielded one point and negative phrases against IPF reduced one point. The IPF cohort was formed using a majority vote of the affirmative or negative entries of EMR texts and imaging/pathology statements. The inclusion criteria was met by 266 patients.

IPF cohort validation

Pirfenidone and nintedanib medication, available since 2013 and 2015 in Finland respectively, was utilized for cohort validation. Of the 993 patients with J84.1 or J84.9 diagnoses, 46 were prescribed pirfenidone or nintedanib. Of these, 43 patients were among those identified with IPF. Two patients with antifibrotic medication lacked HRCT or lung biopsy required for inclusion, and one false negative case was excluded based on text-mining results (3/46, specificity 93.5%).

The specificity of the text mining algorithm was verified by selecting 20 random positively identified patients. Based on manual text validation, IPF was verified in 19 persons. In the remaining patient, IPF was the most likely diagnosis, but interstitial fibrosis due to drug adverse event was not completely excluded (1/20, specificity 95.0%). Randomly selected texts of 10 excluded patients were further assessed for sensitivity. No evident

IPF cases were identified, some were clearly not IPF (e.g. cryptogenic organizing pneumonia; myelofibrosis; or scleroderma with lung involvement). This proved that both the specificity and sensitivity, along with exclusion of non-IPF patients from the cohort, were good.

Lung function

Lung function was assessed by FVC at baseline (± 6 months) and during follow-up. At baseline, 62% of patients had an original structured database spirometry recording available. Text-mining of EMR increased baseline FVC value coverage to 93%. Patients were divided by baseline FVC into groups, mirroring reimbursement restrictions in Finland: (1) FVC >90% predicted; (2) FVC 50–90% predicted; (3) FVC <50% predicted. Lung function was also assessed by diffusion capacity of carbon oxide (DLCO, mmol/min*kPa), available from structured data as an absolute value in 51% of IPF patients.

Time-to-event analyses were used to assess the change from one FVC category to the next or death. Censoring events were antifibrotic treatment initiation, end of study, or lost to follow-up. The association of FVC and DLCO was analysed with Spearman's rank correlation.

Medication

The proportion of patients receiving N-acetylcysteine, oral corticosteroid, or azathioprine was assessed from hospital prescriptions (inpatient/outpatient care) and patient texts. Medication use was defined as the time between the first and the last recording. For medication combinations, overlapping timelines were required.

Survival

Survival was assessed by Kaplan-Meier fits (stratified by baseline FVC category) and Cox-proportional hazard models. Time to event was defined from index to death (event) with initiation of antifibrotic treatment, lost to, or end of follow-up as censoring events. Survival analyses included 260 patients (exclusions: one post-mortem diagnosis, five antifibrotic treatment initiations at index). Cox-proportional hazard models included univariable and multivariable models. FVC was treated as a time varying covariate using all available measures from the follow-up. Categorical FVC groups were treated as time varying covariates and considered 'no return'. Other covariates included data ± 6 months from index.

Oxygen supplementation

To investigate the need for oxygen supplementation, the lending of oxygen concentrators was assessed from the medical device lending database of the HDSWF. O₂ supplementation period included the time from the first device lending day until the device was returned.

Healthcare resource utilization and cost

HCRU included specialty care contacts in the form of in-patient days, out-patient visits at the hospital, emergency room (ER) visits, procedures, surgical operations, imaging, neurophysiology, clinical physiology examinations, and laboratory tests. FVC categories were defined as no return. For each patient the time spent in each FVC category was used to map the corresponding HCRU until end of or lost to follow-up, antifibrotic medication initiation, or death.

Costs were computed utilizing standard HCRU unit costs from the HDSWF 2017 price listing. Each specialty care contact was evaluated by specialty and severity type (normal/demanding visit). Visits lacking these metadata were imputed as the mean costs of all corresponding visits. For prices not found at the HDSWF, other publicly available Finnish price listings were utilized. Operations, procedures, imaging and laboratory tests lacking data in any public price lists were imputed as the mean of all available corresponding prices. Costs were expressed in 2017 euros.

The Turku University Hospital administration approved the study (T76/2018) and the study was performed according to the EU General Data Protection Regulation (GDPR).

Results

Of the 993 patients with J84.1 or J84.9 diagnoses, 266 (27%) were identified as true IPF patients and included in further analyses. IPF patients were mainly identified through HRCT statements (77.1%, N = 205) or the combination of HRCT and biopsy (21.8%, N = 58), while biopsy alone was rare (1.1%, N = 3). The mean follow-up time was 3.03 (SD 2.97) years or 808 patient-years. Patients were most commonly treated with oral corticosteroids (68%) and azathioprine (11.7%), and rarely with N-acetylcysteine (2.6%). The combination of these three drugs was used by 1.1% of the patients.

The mean age at diagnosis was 74 years, with IPF more prevalent in men (64%), [Table 1](#). Mean FVC at index was 77% predicted, with 24% of patients presenting with FVC >90% predicted and 63% with FVC 50-90% predicted. The median number of FVC measures in the cohort was 6

Table 1. Baseline characteristics of IPF patients.

Trait	Value	MISSING, (%)
N	266	
MALE (%)	64%	
Age, years	74.3 ± 8.45	
Follow-up time, years	3.03 ± 2.97	
FVC % predicted	77 ± 20	7%
DLCO (mmol/min*kPa)	4.02 ± 1.27	49%
BMI kg/m ² *	27.8 ± 4.9	14%
Charlson index	2.1 ± 1.45	
Baseline 6 min walking test (m)	335 ± 139	80%
Any 6 min walking test (m)**	349 ± 136	65%
Baseline FVC	FVC>90% pred.; N (%)	64 (24%)
	FVC % predicted	102 ± 10
	FVC 50-90% pred.; N (%)	167 (63%)
	FVC % predicted	72 ± 11
	FVC <50% pred.; N (%)	17 (6%)
	FVC % predicted	39 ± 8
	FVC unknown; N (%)	18 (7%)
	FVC % predicted	NA
Baseline smoking status *	Former, (%)	31%
	Current smoker, (%)	20%
	Never smoked, (%)	41%
	Smoking status unknown, (%)	9%
End of follow up type	Alive 31.12.2017, (%)	41%
	Antifibrotic medication initiated, (%)	16%
	Dead, (%)	42%

*text-mined. Data presented as mean±SD if not otherwise indicated;

**complementing baseline data with data from any time during follow-up; value closest to baseline used if multiple values were present

(IQR 3–12). No trend for improved FVC at diagnosis was observed during the study period ([Figure 1](#)). At the end of follow-up, 16% had initiated antifibrotic medication and 42% of patients had died ([Table 1](#)).

At baseline vs. at end of follow-up, essential hypertension was diagnosed in 33% vs. 48% of patients; chronic ischemic heart disease in 19% vs. 27%. Pneumonia diagnoses increased from 16% to 41%, and chronic obstructive pulmonary disease (COPD) from 8% to 15% ([Table A2](#)).

FVC decline

IPF progression was described as the time from each baseline FVC category to the next. The median time from FVC>90% to below 90% or death was 2.4 years ([Table 2](#)). A change in category was observed in 44 (66%) of these patients and 14% died. Seventeen percent (N = 11) of patients remained in the FVC>90% category when their follow-up ended ([Table 2](#)). Only one patient with baseline FVC>90% reached FVC<50% predicted during follow-up, one third of patients died and follow-up ended in 58% of patient before this. Moreover, 6.3% of all patients initiated antifibrotic treatment and were censored.

In patients with baseline FVC of 50-90% predicted, 18% reached an FVC<50% and 26% died. Censoring




Figure 1. FVC (% predicted) at diagnosis by calendar year.

Table 2. Time to change of FVC category according to baseline status, Kaplan-Meier analysis.

Baseline value		FVC >90%	FVC >90%	FVC 50-90%
Event value		↓ <90%	↓ <50%	↓ <50%
N total		64	64	166
Time to event, years; median [95% CI]		2.4 [1.1–3.1]	4.9 [3.1 – NA]	4.0 [2.8–5.4]
Event	FVC below event value, N (%)	42 (66%)	1 (1.6%)	30 (18%)
	Dead, N (%)	9 (14%)	21 (33%)	43 (26%)
	Transplant, N (%)	0	0	0
Censoring	End of follow-up [FVC remained above event value], N (%)	11 (17%)	37 (58%)	60 (36%)
	Antifibrotic treatment initiated, N (%)	1 (1.6%)	4 (6.3%)	32 (19%)
	Lost to follow-up, N (%)	1 (1.6%)	1 (1.6%)	1 (0.6)

due to antifibrotic treatment was noted in 19% and end of follow-up in 36% before a category drop (Table 2).

DLCO was the best in those with baseline FVC >90% predicted and decreased with worsening FVC (median, IQR; FVC>90%: 4.4, 3.5–5.3; FVC 50-90%: 3.7, 3.1–4.7; FVC<50% 3.3, 3.3–3.6 mmol/min*kPa, $p = 0.002$). Long term continuous oxygen supplementation is provided to patients by clinical indication e.g. low oxygen at rest or exercise. Overall, 27% of patients utilized oxygen

supplementation devices, 12.7% of patients with FVC >90% predicted; 15.7% of those with 50-90% predicted; and 47.9% of those with FVC<50% predicted.

Mortality

The median survival of the IPF cohort was 5.0 years (95% CI: 4.0–6.7), Figure 2. Median survival decreased by worsening FVC category from 6.7 years at baseline




Figure 2. Overall survival of IPF patients (left) and stratified by baseline FVC (right) to FVC>90%; 50-90%; <50% predicted; and unknown FVC. Time is in years. Censoring events: antifibrotic treatment initiation, lost to follow-up, end of follow-up.

FVC>90% predicted to 5.3 years in FVC 50-90% predicted, and 0.7 years in patients with FVC<50% predicted (Figure 2). At the end of follow-up, 31% of patients with baseline FVC >90% predicted had died; 38% of FVC 50-90%, 82% of FVC<50%, and 88% of FVC unknown.

In the multivariable Cox model, with FVC>90% as reference, FVC 50-90% was associated with a 2-fold increase in mortality [HR 1.98 (95% CI: 0.91–2.28), $p = 0.084$], but the association did not reach statistical significance. Patients with FVC <50% predicted, presented a significant 8.8-fold increased risk of death. Independent predictors of death were low BMI, and baseline oral corticosteroid (OCS) use

(Figure 3, Table A3, model 1). Treating FVC as a continuous variable, each percent decline increased the mortality risk by 4%. Further, in this model higher age at diagnosis and low BMI (<20 kg/m²) were independently associated with mortality (Table A3, model 2).

Healthcare resource utilization

Healthcare resource utilization correlated with disease severity. IPF patients were on average hospitalized 5.5 days per patient-year. This increased by deteriorating FVC category and was 1.2-fold higher in patients




Figure 3. Cox regression analysis of overall mortality in IPF patients. FVC group was used as a time-varying covariable. BMI-body mass index, OCS-oral corticosteroid.

with baseline FVC 50-90% predicted, and 2.8-fold higher in patients with FVC <50% predicted compared to FVC>90% predicted (Figure 4, Table A4). Unknown FVC presented an 8.1-fold increase in inpatient days per patient-year compared to FVC>90% predicted.

Overall, IPF patients utilized 4.7 million euros worth of specialty care resources between 2005 and 2017, calculated with 2017 prices. Incremental overall HCRU costs of patients with FVC 50-90% predicted

compared to FVC>90% was 835€ per patient-year, increasing to 5,166€ per patient-year at FVC<50% predicted (Figure 4, Table A4). Lung transplanted patients and those lacking an FVC measure had the highest incremental costs (Figure 4, Table A4). Highest cost drivers were hospital inpatient days in all categories, with an average of 2,172€ per patient-year, followed by visits and procedures (1,290€ and 1,045€ per patient-year, Table A4).




Figure 4. a) Hospital inpatient days, out-patient visits and emergency room visits (ER) per patient-year, stratified by FVC category. b) Overall healthcare resource utilization related costs (€) per patient-year, at specialty care of IPF patients, stratified by FVC category or lung transplant. The incremental costs per worsening category compared to FVC>90% predicted are presented on top of/in bars with grey.

Discussion

This retrospective registry study investigated 266 IPF patients during the years 2005–2017 for FVC decline, mortality and specialty care associated healthcare resource utilization. The Turku University Hospital is the sole provider of secondary care for severe respiratory diseases at the HDSWF, making data from the 480 000 catchment population representative. This study describes and defines an IPF population using data lakes for the first time. Investigating disease severity by FVC, over a period exceeding ten years, yielded insights on the disease course and healthcare resource utilization. Notably, one fourth of patients presented with mild disease and were unentitled to modern IPF treatment reimbursement.

Patient inclusion was based on positive HRCT and/or biopsy EMR results in combination with clinical diagnosis, whilst excluding other causes. This identified IPF in 27% of patients with diagnose codes J84.1 or J84.9. The proportion is consistent with previous studies showing that 20–30% of ILD patients have IPF [9,10].

Diagnosis over time

IPF guidelines and available treatment options have directed IPF care towards precise and earlier diagnosis [1,5,6]. Yet, no increase in FVC by year of diagnosis was observed in this study. This was surprising considering the evolution of diagnosis and the study period covering over 10 years of data, however, HRCT and biopsy criteria have been included in the diagnostic procedure in Finland since the beginning of the study period. A relatively preserved lung function at diagnosis, also seen in other Finnish studies, may partly explain this [9]. IPF diagnosis is often delayed up to 2 years from symptom onset to clinical diagnosis, by subtle progressive symptoms and non-specific clinical and physical presentation [25,26]. Diagnosis delays independently increase mortality risk, highlighting the importance of early diagnosis [25]. Additionally, clinical studies with pirfenidone and nintedanib show that early initiation of disease modifying treatment can postpone irreversible deteriorative changes in lung function [2,12,13,15].

Oxygen supplementation and quality of life

Impaired functional capacity, oxygen supplementation, and dyspnoea negatively affect the quality of life of IPF patients [27]. Unfortunately, quality of life data was not available in this study, as the 6 min walking test results were lacking for most of the patients, and the reported

diffusion capacity results are more guiding in nature. Still, 13% of patients with FVC>90% received oxygen supplementation, supporting the notion that poor diffusion capacity may reduce quality of life already with mild disease. Whether they represent a sub-phenotype of IPF needs further research.

Mortality

A competing risk between FVC decline and mortality was observed. Notably, 14% of patients with baseline FVC>90% died before FVC<90% predicted was registered. Similarly, in the other baseline FVC categories one third of patients died before a change to the next category could be seen. Likely these patients represent rapid progressors [28]. Those lacking FVC data had the shortest survival, possibly explained by inability due to advanced disease, or incapacity due to morbidity, to perform spirometry. In addition to FVC, low BMI and OCS use were associated with poor survival. However, as exacerbations could not be evaluated, the context of OCS could not be assessed.

Median overall survival of IPF patients has been assessed in different studies with different methodological criteria to be 2–4 years [25,28,29] and 5-year survival to be 30% [30]. In this study the median overall survival for the whole cohort was 5.0 years, with 6.7 years for those with baseline FVC>90% predicted and decreasing by deteriorating lung function to 0.7 years for patients with FVC<50% predicted. In another study with differing FVC categories, mild and moderate-severe baseline FVC showed a similar trend in life-expectancy [20]. Importantly, we show a 9-fold increased mortality risk in patients with FVC <50% compared to FVC>90% predicted. Further, a 1% FVC drop was associated with a 4% increase in mortality, increasing mortality risk exponentially for each %-decline. The importance of these results is emphasized by the fact that prior survival data by baseline FVC categories are meagre.

Healthcare resource utilization

IPF progression, comorbidities and lung transplantations are key events affecting healthcare costs through hospital stays, visits and medication costs [23]. This is further supported by this study, where HCRU was mainly driven by hospital inpatient days. IPF patients presented an average of 5.5 hospital inpatient days per patient-year, in line with the previously reported 3.1–5.3 inpatient days per patient-year [19,24]. This study also showed, for the first time, an increase in hospital inpatient days by deteriorating FVC group

compared to FVC>90% predicted. Correspondingly, IPF patients had on average 10.9 outpatient visits per patient-year, increasing 1.1-fold at FVC 50-90% predicted compared to FVC>90%, and 1.2-fold for those with FVC<50%. This is in line with other claims based studies reporting outpatient visits in the range of 5.7–28 per patient-year, however these studies did not assess HCRU at different disease stages [19,24,31].

Overall, HCRU costs were 5827€ per patient-year, which is a conservative estimate counting only direct specialty care related costs. Costs and mortality are substantially affected by exacerbations [21,23,32] but they could not be assessed in this study. Especially the prevalence of exacerbations at different disease severities, and their impact on HCRU and mortality will need further studies.

The strengths of the study include data collection in routine care that is not affected by strict inclusion or exclusion criteria. Further, text-mining tool utilization allowed for the exclusion of non-IPF patients from the cohort. The study period of 13 years led to a reliable assessment of mortality data.

Limitations are that as data was collected from a specific geographical region results are possibly affected by treatment praxis. However, big geographical differences are not expected, as the natural disease progression is described. Other limitations include those associated with real world data where all variables are not available for all patients. Further, incidence and prevalence were not investigated; however, this data could contribute to discussions on whether increasing IPF incidence is real or resulting from different methodologies and heterogenous patient populations [33].

Conclusions

This study raises several considerations for the care of IPF patients in the future. First, there is still a need to improve IPF diagnosis and enhance the collaboration between primary and specialty care to detect IPF at an early stage, as no improvement in FVC at diagnosis was observed during the study period. Furthermore, FVC alone may not always be an adequate measure of disease severity, rather efforts should be made to assess the quality of life in these patients utilizing other clinical indicators. As both the economic and the humanistic burdens of disease worsen with advancing disease, it is of outmost importance to postpone FVC decline in order to increase the IPF patients' quality of life.

Acknowledgments

Juha Varjonen at Auria Clinical Informatics at the Turku University Hospital is acknowledged for his input on data extraction. Kirsi Tolonen at Boehringer Ingelheim is acknowledged for

her comments during protocol development. Jaana Ahlmaa at Medaffcon is acknowledged for writing assistance.

Notes on contributors

Mariann I Lassenius, PhD, is currently the Real World Evidence Lead and Senior Scientific Advisor at the healthcare consultancy company Medaffcon Oy. Before this she earned her doctoral degree within the field of diabetes research at the University of Helsinki, Department of Nephrology and at the Folkhälsan Research Institute, Helsinki, Finland.

Iiro Toppila, M.Sc. (Tech.), is currently Data Analysis Lead and biostatistician at the healthcare consultancy company Medaffcon Oy. He earned his Master's degree from Aalto University, Finland, with Bioinformatics and Computational Systems Biology as his major.

Nora Pöntynen, PhD, is currently Medical Manager at Boehringer Ingelheim Finland Ky. Before that she held several positions in the academia, worked with IPR and in the pharmaceutical industry. She earned her MSc in cell biology from Åbo Akademi University, Finland, did a Maîtrise de Biologie Cellulaire et Physiologie at the Université de Reims Champagne-Ardennes, France and her doctoral degree focused on a rare monogenic autoimmune disease at the Department of Medical Genetics, University of Helsinki, Finland.

Laura Kasslin, M.Sc. (Pharm.), is currently Head of Market Access and External Affairs at Boehringer-Ingelheim Finland Ky. She earned her Master's degree from the University of Helsinki, Finland, with Pharmacology as her major.

Jaana Kaunisto, MD is working as a pulmonologist at Turku University Hospital (Finland). Additionally, she is a PhD student and preparing a dissertation on the epidemiology and management of idiopathic pulmonary fibrosis.

Maritta Kilpeläinen, MD, PhD is currently the Head of the Department of Pulmonary Medicine at Turku University Hospital and special advisor in allergology. Earlier she has worked as a consultant in pulmonary diseases and allergology at the Turku University Hospital and as senior lecturer in at the University of Turku, Finland.

Tarja Laitinen, MD PhD is currently the Director of Research at the Tampere University Hospital. Before that she held several positions in the academia as well in the biotech industry: professorships in Respiratory Diseases, Biobank Research, and Clinical Informatics at the University of Turku and she has been the head of the Department of Pulmonary Diseases at the University Hospital of Turku. She has been the CSO and co-founder of the BioHealthCareInformatics Company Geneos Ltd. Her post-doctoral education was done in the Centre for Genome Research, MIT, USA.

Declaration of interest statement

MIL and IT are employees of Medaffcon Oy. NP and LK are employees of Boehringer Ingelheim Finland. JK has

participated in congresses with support from Boehringer Ingelheim and Sanofi Genzyme. MK has nothing to declare. TL has served as a scientific advisory board member and participated in congresses with support from GSK, Boehringer Ingelheim, AstraZeneca, Teva, Roche and MSD.

Funding

This study was funded by Boehringer Ingelheim.

References

- [1] Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med.* 2011;183:788–824.
- [2] Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. *Lancet.* 2017;389:1941–1952.
- [3] Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). *Am J Respir Crit Care Med.* 2000;161:19.
- [4] Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a fleischner society white paper. *Lancet Respir Med.* 2018;6:138–153.
- [5] Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. *Am J Respir Crit Care Med.* 2018;198:e44–e68.
- [6] Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. *Am J Respir Crit Care Med.* 2015;192:e3–e19.
- [7] Sköld CM, Bendstrup E, Myllärniemi M, et al. Treatment of idiopathic pulmonary fibrosis: a position paper from a nordic expert group. *J Intern Med.* 2017;281:149–166.
- [8] Hodgson U. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. *Thorax.* 2002;57:338–342.
- [9] Kaunisto J, Kelloniemi K, Sutinen E, et al. Re-evaluation of diagnostic parameters is crucial for obtaining accurate data on idiopathic pulmonary fibrosis. *BMC Pulm Med.* [Internet] 2015 [cited 2019 Jan 21]; 15. Available from: <http://bmcpulmed.biomedcentral.com/articles/10.1186/s12890-015-0074-3>
- [10] Sgalla G, Biffi A, Richeldi L. Idiopathic pulmonary fibrosis: diagnosis, epidemiology and natural history: IPF: diagnosis, epidemiology, course. *Respirology.* 2016;21:427–437.
- [11] Kennedy-Martin T, Curtis S, Faries D, et al. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. *Trials.* [Internet] 2015 [cited 2019 Jan 15]; 16. Available from: <http://trialsjournal.biomedcentral.com/articles/10.1186/s13063-015-1023-4>
- [12] King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. *N Engl J Med.* 2014;370:2083–2092.
- [13] Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. *Eur Respir J.* 2016;47:243–253.
- [14] Richeldi L, Cottin V, Du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS® trials. *Respir Med.* 2016;113:74–79.
- [15] Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *N Engl J Med.* 2014;370:2071–2082.
- [16] Albera C, Costabel U, Fagan EA, et al. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. *Eur Respir J.* 2016;48:843–851.
- [17] Kolb M, Richeldi L, Behr J, et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. *Thorax.* 2017;72:340–346.
- [18] 284 Nintedanib och pirfenidon [Internet]. *kela.sv* [cited 2019 Jan 22]. Available from: <https://www.kela.fi/web/sv/lakemedel284>.
- [19] Collard HR, Ward AJ, Lanes S, et al. Burden of illness in idiopathic pulmonary fibrosis. *J Med Econ.* 2012;15:829–835.
- [20] Jo HE, Glaspole I, Moodley Y, et al. Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry. *BMC Pulm Med.* [Internet] 2018 [cited 2019 Jan 21]; 18. Available from: <https://bmcpulmed.biomedcentral.com/articles/10.1186/s12890-018-0575-y>
- [21] Song JW, Hong S-B, Lim C-M, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. *Eur Respir J.* 2011;37:356–363.
- [22] Tarride J-E, Hopkins RB, Burke N, et al. Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada. *Clin Outcomes Res.* 2018;10:127–137.
- [23] Vaidya S, Hibbert CL, Kinter E, et al. Identification of key cost generating events for idiopathic pulmonary fibrosis: a systematic review. *Lung.* 2017;195:1–8.
- [24] Wu N, Yu YF, Chuang -C-C, et al. Healthcare resource utilization among patients diagnosed with idiopathic pulmonary fibrosis in the USA. *J Med Econ.* 2015;18:249–257.
- [25] Lamas DJ, Kawut SM, Bagiella E, et al. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. *Am J Respir Crit Care Med.* 2011;184:842–847.
- [26] Purokivi M, Hodgson U, Myllärniemi M, et al. Are physicians in primary health care able to recognize pulmonary fibrosis? *Eur Clin Respir J.* 2017;4:1290339.
- [27] Graney BA, Lee JS. Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives. *Patient Relat Outcome Meas.* 2018;9:321–328.
- [28] Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2011;183:431–440.
- [29] Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. *JAMA.* 2013;309:2232.

- [30] Vancheri C, Failla M, Crimi N, et al. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. *Eur Respir J.* 2010;35:496–504.
- [31] Raimundo K, Chang E, Broder MS, et al. Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study. *BMC Pulm Med.* [Internet] 2016 [cited 2019 Jan 21]; 16. Available from: <http://www.biomedcentral.com/1471-2466/16/2>
- [32] Teramachi R, Kondoh Y, Kataoka K, et al. Outcomes with newly proposed classification of acute respiratory deterioration in idiopathic pulmonary fibrosis. *Respir Med.* 2018;143:147–152.
- [33] Hutchinson J, Fogarty A, Hubbard R, et al. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. *Eur Respir J.* 2015;46:795–806.

Appendices

Table A1. Text patterns used to select the IPF patient cohort from the initial cohort of 993 patients with J84.1 or J84.9 diagnoses.

Image text statements	Pro IPF: honeycomb, UIP, IPF, idiopathic pulmonary fibrosis, traction bronchiectasis, reticular opacities Against IPF: NSIP-, COP-, LIP, alveolitis, asbestosis, stone dust lung, silicosis, eosinophilic pneumonia, hypersensitivity pneumonia, emphysema
Pathology statement text of lung biopsy	Pro IPF: fibroblast focus, honeycomb, UIP, IPF, idiopathic pulmonary fibrosis Against IPF: unspecific/granulomatous inflammation, eosinophilia, NSIP, COP, LIP, DIP, bronchiolitis, hypersensitivity pneumonia
Clinical diagnosis from lung view of EMR	Pro IPF: honeycomb, UIP, IPF, idiopathic pulmonary fibrosis, progressive restrictive lung disease/fibrosis, auscultation inspiratory rasping sound of small alveoli, no autoimmune antibodies, ANCA antibodies not elevated, ANA antibodies not elevated, ENA antibodies not elevated, rheumatoid factor not elevated, citrulline antibodies not elevated, DNA antibodies not elevated, ssDNA antibodies not elevated, SS-A antibodies not elevated, SS-B antibodies not elevated, anti SM not elevated, nucleus antibodies not elevated, MPO antibodies not elevated Against IPF: Rheumatoid arthritis, SLE, MCTD, Sjögren syndrome, scleroderma, myositis, autoimmune fibrosis, fibroelastosis, bronchiolitis, NSIP, COP, LIP, DIP, asbestosis, significant asbestos exposure, hypersensitivity pneumonia, radiation pneumonitis, condition after radiation, vasculitis, eosinophilic pneumonia, autoimmune antibodies elevated, ANCA antibodies elevated, ANA antibodies elevated, ENA antibodies elevated, rheumatoid factor elevated, citrulline antibodies elevated, DNA antibodies elevated, ssDNA antibodies elevated, SS-A antibodies elevated, SS-B antibodies elevated, anti SM elevated, nucleus antibodies elevated, MPO antibodies elevated

All text patterns were searched in Finnish (as the patient texts are written in Finnish), including plausible different writing forms, most common typing errors and different ways of specifying negative phrases. The performance of text mining cohort formation was assessed by manual validation of randomly selected patients included and excluded from the cohort, and by assessing use of IPF specific antifibrotic medications (pirferidone or nintedanib), see material and methods.

Table A2. Comorbidities in IPF patients at end of follow-up and their frequency in the patients at baseline.

ICD10	End of follow-up	Baseline	Description
J84	100%	100%	Other interstitial pulmonary diseases
R91	59%	40%	Abnormal findings on diagnostic imaging of lung
I10	48%	33%	Essential (primary) hypertension
J18	41%	16%	Pneumonia, organism unspecified
R06	35%	27%	Abnormalities of breathing
H25	33%	17%	Senile cataract
Z01	29%	21%	Other special examinations and investigations of persons without complaint or reported diagnosis
I25	27%	19%	Chronic ischaemic heart disease
E11	25%	18%	Non-insulin-dependent diabetes mellitus
Z03	23%	11%	Medical observation and evaluation for suspected diseases and conditions
E78	22%	14%	Disorders of lipoprotein metabolism and other lipidaemias
I48	21%	12%	Atrial fibrillation and flutter
I50	20%	6%	Heart failure
R05	18%	15%	Cough
G47	17%	11%	Sleep disorders
H90	15%	11%	Conductive and sensorineural hearing loss
N40	15%	11%	Hyperplasia of prostate
J44	15%	8%	Other chronic obstructive pulmonary disease
J92	15%	8%	Pleural plaque
M17	14%	13%	Gonarthrosis [arthrosis of knee]
Z71	14%	8%	Persons encountering health services for other counselling and medical advice, not elsewhere classified
R10	14%	8%	Abdominal and pelvic pain
M16	12%	10%	Coxarthrosis [arthrosis of hip]
R07	12%	7%	Pain in throat and chest
I20	12%	8%	Angina pectoris
J96	12%	2 %	Respiratory failure, not elsewhere classified
K21	12%	7%	Gastro-oesophageal reflux disease
Z95	11%	7%	Presence of cardiac and vascular implants and grafts
I21	11%	4 %	Acute myocardial infarction
C44	11%	8%	Other malignant neoplasms of skin
E03	11%	8%	Other hypothyroidism
J45	11%	8%	Asthma
L57	10%	6%	Skin changes due to chronic exposure to nonionizing radiation
M54	10%	5 %	Dorsalgia
Z76	10%	6%	Persons encountering health services in other circumstances

Table A3. Cox regression of overall mortality, with baseline FVC as time-varying class variable (multivariable 1) or continuous variable (multivariable 2).

	Univariable			Multivariable (1)			Multivariable (2)		
	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value
FVC (continuous, time-varying)	0.96	0.95–0.98	<0.001				0.96	0.95–0.97	<0.001
FVC class	1	ref.	–	1	ref.	–			
(time-varying)									
>90%	1.77	0.87–3.61	0.114	1.98	0.91–4.28	0.084			
<50%	5.58	2.64–11.81	<0.001	8.75	3.79–20.18	<0.001			
Transplanted	2.03	0.25–16.81	0.511	NA*	NA*	NA*			
Unknown	17.36	7.47–40.32	<0.001	15.02	4.94–45.71	<0.001			
Age	1.04	1.02–1.07	<0.001	1.04	1.01–1.07	0.013	1.04	1.01–1.07	0.018
Sex	1	ref.	–	ref.	–	–	ref.	1	–
Male	0.59	0.39–0.88	0.010	0.72	0.43–1.20	0.209	0.82	0.48–1.40	0.466
Female	3.06	1.23–7.60	0.016	4.38	1.64–11.74	0.003	2.92	1.02–8.31	0.045
BMI	1	ref.	–	1	ref.	–	ref.	1	–
<20	0.95	0.56–1.60	0.833	1.16	0.67–2.01	0.596	1.19	0.66–2.16	0.561
20–25	0.84	0.48–1.46	0.529	0.86	0.48–1.55	0.617	0.95	0.51–1.77	0.868
≥30	1	ref.	–	1	ref.	–	ref.	1	–
Smoking	1.41	0.92–2.16	0.114	1.44	0.83–2.52	0.195	1.24	0.70–2.20	0.463
Non-smoker	0.58	0.33–1.03	0.063	0.79	0.39–1.58	0.500	0.75	0.38–1.49	0.412
former	0.69	0.34–1.42	0.319	1.18	0.80–4.15	0.156	1.33	0.57–3.12	0.507
Current	1.11	0.97–1.28	0.127	0.98	0.82–1.16	0.785	1.07	0.9–1.28	0.452
Missing	1	ref.	–	1	ref.	–	ref.	1	–
Charlson index	2.03	1.38–3.00	<0.001	1.61	1.03–2.49	0.035	1.55	0.98–2.45	0.062
BL OCS									
No									
Yes									

NA* patients with lung transplant dropped due to missing covariate values, BL- baseline, OCS-oral corticosteroids.

Table A4. Overall healthcare resource utilization related costs per FVC or lung transplant categories.

HCRU TYPE	CLASS	EVENTS, N	COST, €	EVENTS PER PATIENT YEAR	COST PER PATIENT YEAR, €
OUTPATIENT VISITS	ALL	8,817	885,219	10.91	1,095.53
	FVC >90%	1,380	137,768	9.49	947.43
	FVC 50-90%	5,567	557,783	10.42	1,043.94
	FVC <50%	1,218	124,907	11.52	1,181.68
	Transplant	538	53,257	50.78	5,026.36
	Unknown FVC	114	11,504	9.49	957.57
ER VISITS	ALL	804	156,780	1.00	194.03
	FVC >90%	105	20,475	0.72	140.81
	FVC 50-90%	482	93,990	0.90	175.91
	FVC <50%	156	30,420	1.48	287.79
	Transplant	20	3,900	1.89	368.08
	Unknown FVC	41	7,995	3.41	665.49
HOSPITAL INPATIENT DAYS	ALL	4,451	1,755,334	5.51	2,172.36
	FVC >90%	528	198,155	3.63	1,362.71
	FVC 50-90%	2,363	887,994	4.42	1,661.96
	FVC <50%	1,084	469,430	10.26	4,441.03
	Transplant	124	48,637	11.70	4,590.34
	Unknown FVC	352	151,118	29.30	12,578.79
PROCEDURES	ALL	2,638	844,370	3.26	1,044.97
	FVC >90%	418	124,346	2.87	855.12
	FVC 50-90%	1,605	517,056	3.00	967.72
	FVC <50%	464	162,389	4.39	1,536.28
	Transplant	73	18,311	6.89	1,728.23
	Unknown FVC	78	22,267	6.49	1,853.50
OPERATIONS	ALL	266	369,096	0.33	456.78
	FVC >90%	38	49,381	0.26	339.59
	FVC 50-90%	169	245,081	0.32	458.69
	FVC <50%	50	64,719	0.47	612.27
	Transplant	3	4,150	0.28	391.68
	Unknown FVC	6	5,765	0.50	479.87
IMAGING ETC	ALL	4,787	445,906	5.92	551.84
	FVC >90%	620	58,040	4.26	399.14
	FVC 50-90%	3,036	275,254	5.68	515.16
	FVC <50%	866	80,164	8.19	758.39
	Transplant	145	18,875	13.69	1,781.42
	Unknown FVC	120	13,573	9.99	1,129.80
LABS	ALL	117,216	251,783	145.06	311.60
	FVC >90%	14,440	27,268	99.30	187.52
	FVC 50-90%	63,966	130,236	119.72	243.75
	FVC <50%	26,138	61,400	247.28	580.87
	Transplant	6,852	17,487	646.69	1,650.44
	Unknown FVC	5,820	15,392	484.45	1,281.19
TOTAL COSTS	ALL	–	4,708,488	–	5,827.12
	FVC >90%	–	615,433	–	4,232.32
	FVC 50-90%	–	2,707,395	–	5,067.13
	FVC <50%	–	993,429	–	9,398.31
	Transplant	–	164,617	–	15,536.55*
	Unknown FVC	–	227,614	–	18,946.20

*including post-transplant care only.